Facebook
Twitter
LinkedIn
ForwardLongitudinally Managing Rheumatoid Arthritis
This CME/CE-accredited CME Snapshot™ series of educational videos has been created for rheumatologists and other clinicians involved in treating patients with rheumatoid arthritis (RA). During each 15-minute activity, two expert rheumatologists focus on a specific aspect of long-term RA management, including practical advice on implementing international treat-to-target guidelines as well as the mechanistic profiles and clinical evidence for therapies designed to inhibit signaling via interleukin-6 (IL-6) or members of the Janus kinase (JAK) family of enzymes. Some of the modules also include 3D-animated elements to illustrate the relationships between the heterogeneous pathophysiologic mechanisms underlying RA and certain targeted biologic or synthetic disease-modifying treatment options.
Target Audience
This activity has been designed to meet the educational needs of rheumatologists and other clinicians involved in the ongoing management of patients with RA.
Learning Outcome Statements
At the conclusion of this activity:
KNOWLEDGE: Participants will self-report knowledge gained based on current best practices and therapies for treating and managing Rheumatoid Arthritis.
COMPETENCE/SKILL: Participants will self-report intent to change practice by applying knowledge gained based on current best practices and therapies for treating and managing Rheumatoid Arthritis.
Educational Objectives
Upon completion of this activity, participants will be better able to do the following:
- Implement treat-to-target strategies to reflect shared clinical decision making, comprehensive evaluations of RA activity and other patient-specific factors
Faculty
 | Leonard H. Calabrese, DO Professor of Medicine Cleveland Clinic Lerner College of Medicine, Case Western Reserve University Vice Chair, Department of Rheumatic and Immunologic Diseases R.J. Fasenmyer Chair of Clinical Immunology Cleveland Clinic Foundation Cleveland, Ohio |
| John R. P. Tesser, MD, FACP, FACR |
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Faculty or Presenter | Relationship Identified With: |
| Leonard H. Calabrese, DO | Consultant/Advisor: AbbVie Inc.; Crescendo Bioscience, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Horizon Pharma plc; Janssen Pharmaceuticals, Inc.; Medimmune, LLC; Pfizer Inc.; UCB, Inc. Speakers’ Bureau: AbbVie Inc.; Crescendo Bioscience, Inc.; Genentech, Inc.; Horizon Pharma plc; Janssen Pharmaceuticals, Inc.; Medimmune, LLC; UCB, Inc. |
| John R. P. Tesser, MD | Consultant/Advisor: Eli Lilly and Company; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme Speakers’ Bureau: AbbVie Inc.; Eli Lilly and Company; Genentech, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme Research Grant: AbbVie Inc.; Eli Lilly and Company; Genentech, Inc.; Gilead Sciences, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi-Genzyme Employment (spouse): Regeneron Pharmaceuticals, Inc. |
Non-faculty: Rose O’Connor, PhD; Jim Kappler, PhD; Sandy Breslow; Alison Kemp; Marilu Kelly, MSN, RN, CNE; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Financial Support
This activity has been supported by independent educational grants from Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals.
Provider Information
Jointly provided by the Elsevier Office of Continuing Medical Education, Elsevier and Integritas Communications.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE CREDIT (NURSES)
This continuing nursing education activity, provided by Elsevier, awards 0.25 contact hours for nurses. Elsevier is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EOCME, Elsevier, and Integritas Communications.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
For all CNE inquiries or special needs, please contact p.harvey@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Elsevier, Integritas Communications, Gilead Sciences, Inc., and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Available Credit
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Nursing Contact Hours
- 0.25 Non-physician